Nothing Special   »   [go: up one dir, main page]

Mandrell et al., 1989 - Google Patents

Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination

Mandrell et al., 1989

View PDF
Document ID
13516451031478504646
Author
Mandrell R
Zollinger W
Publication year
Publication venue
Infection and immunity

External Links

Snippet

Antibody levels in 41 sets of human acute-and convalescent-phase meningococcal sera were compared with those in 23 sets of human prevaccination and 2-week postvaccination sera. We used a modification of a solid-phase radioimmunoassay (SPRIA) technique to test …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia

Similar Documents

Publication Publication Date Title
Mandrell et al. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination
Zangwill et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel
Rosenqvist et al. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies
Borrow et al. Neisseria meningitidis group B correlates of protection and assay standardization—international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005
Virji et al. Variations in the expression of pili: the effect on adherence of Neisseria meningitidis to human epithelial and endothelial cells
Achtman et al. A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A
Wedege et al. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting
Inzana et al. Serotype specificity and immunogenicity of the capsular polymer of Haemophilus pleuropneumoniae serotype 5
Kim et al. Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular and class 1, 2, and 3 protein epitopes
Moran et al. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity
Ala'Aldeen et al. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains
Litt et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease
Kim et al. Electromorphic characterization and description of conserved epitopes of the lipooligosaccharides of group A Neisseria meningitidis
Black et al. Neisserial antigen H. 8 is immunogenic in patients with disseminated gonococcal and meningococcal infections
Guttormsen et al. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease
Soininen et al. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?
Straubinger et al. Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi
Poolman et al. Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies
Brookes et al. Development of a large scale human complement source for use in bacterial immunoassays
Loeb et al. Human antibody response to individual outer membrane proteins of Haemophilus influenzae type b
Michaelsen et al. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria
Estabrook et al. The immune response of children to meningococcal lipooligosaccharides during disseminated disease is directed primarily against two monoclonal antibody-defined epitopes
Zollinger et al. Meningococcal vaccines—present and future
Bevanger et al. Competitive enzyme immunoassay for antibodies to a 43,000-molecular-weight Francisella tularensis outer membrane protein for the diagnosis of tularemia
MÆLAND et al. Serum antibodies to cross‐reactive Neisseria outer membrane antigens in healthy persons and patients with meningococcal disease